Genentech Receives FDA approval for Actemra SC for the Treatment of Active Systemic JIA in patients aged ≥2 yrs.

 Genentech Receives FDA approval for Actemra SC for the Treatment of Active Systemic JIA in patients aged ≥2 yrs.

Genentech Receives FDA approval for Actemra SC for the Treatment of Active Systemic JIA in patients aged ≥2 yrs.

Shots:

  • The FDA approval is based on P-I JIGSAW-118 (N=51) study assessing PK/PD with appropriate dosage regimen of Actemra SC (aged <17yrs) with range of BWs (weight <30 kg administering 162 mg BID for 10 days; weight ≥30 kg administering 162 mg qw for 52 wks.) in children with sJIA
  • Actemra SC treated patients demonstrated 41% ISRs vs patients treated with Actemra SC for other approved indications. Actemra’s SC efficacy is based on PK disclosure and extrapolation evaluated from Actemra IV & Actemra SC in sJIA & RA patients respectively
  • Actemra can be administered alone or in combination with MTX in sJIA patients. Actemra IV was approved by FDA in 2011 for patients aged ≥2 yrs. with sJIA

Click here to read full press release/ article | Ref: Genentech | Image: CNN

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post